NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Company watch  «  1  2  3  4  5  » 
found files: 574
Eli Lilly & Co »04/05/2007 [Company watch]
Lilly Announces Senior Leadership Changes

Alex M. Azar II to join Lilly as senior vice president of corporate affairs and communications; Anne Nobles to assume role of chief compliance officer...   more»

Eli Lilly & Co »16/04/2007 [Company watch]
Lilly Reports Strong First-Quarter Results; Raises Full-Year Sales and EPS Guidance

Eli Lilly and Company (NYSE: LLY) today announced strong financial results for the first quarter of 2007 and raised its full-year sales and adjusted earnings per share guidance. First-Quarter Highlights * Sales increased 14 percent, to $4.226 billion....   more»

Wyeth »27/04/2007 [Company watch]
Wyeth Chief Financial Officer and Vice Chairman Kenneth J. Martin to Leave the Company

Madison, N.J., April 27, 2007 – Wyeth (NYSE: WYE) today announced that Chief Financial Officer (CFO) and Vice Chairman Kenneth J. Martin has announced plans to leave the Company at the end of June to pursue personal interests. Mr. Martin joined the Company in 1984 and has served as Chief Financial Officer since 2000. Wyeth plans to name a new CFO in advance of Mr. Martin’s departure. "Ken Martin has played key roles at Wyeth for many years and has been an important contributor to our success," says Robert Essner, Chairman and Chief Executive Officer, Wyeth...   more»

SinoBiomed »10/05/2007 [Company watch]
SinoBiomed facility gets GMP certification from SFDA

Chinese State Food and Drug Administration (SFDA) has recertified Shanghai Wanxing Bio-pharmaceuticals’ recombinant human interferon production plant as a Good Manufacturing Practice (GMP) facility. Shanghai Wanxing Bio-pharmaceuticals is a 82 percent owned subsidiary of China-based SinoBiomed. The 2,500 sq mt plant passed the local GMP re-certification inspection that the SFDA conducted from April 12 to 14, 2007 in Shanghai. The facility produces recombinant human interferon powder for injection. Recombinant human interferon is widely used for treating chronic hepatitis B, hepatitis C, a number of viral infections, and tumors. In meeting Chinese national drug GMP certification standards, the plant's heating ventilation air conditioning system achieved a grade of 100 in the SFDA’s air cleanliness classification, equivalent to a B grade in the US air cleanliness classification. The facility has one of China's largest production capacities and has produced some 12 million doses of recombinant human interferon since its initial five-year certification on December 12, 2001. The recertification authorizes production for another five-year term, ensuring quality control for the product as Shanghai Wanxing expands national and international distribution....   more»

China Biopharmaceuticals Holdings »10/05/2007 [Company watch]
China Biopharmaceuticals Holdings (CHBP) has named new officers and directors for its organization

The company has named Ms Zhang Jian as Chairwoman of the Board of Directors, Mr Shi Mingsheng as Chief Operating Officer and Mr Ding Weihua as member of the Board of Directors. The appointments come into effect from April 30, 2007. Ms Zhang Jian served as the General Manager of Suzhou Erye Pharmaceutical Company Limited (Erye) since 2003. Prior to being the General Manager for Erye, she served for more than five years as the deputy general manager of Suzhou Pharmaceutical Company. Ms Zhang has extensive background and experience in the pharmaceuticals industry having worked in various managerial positions and various aspects of the industry. She is known to be an expert in managing the growth of the company. In her new position, she will be overseeing the company's strategic growth and handle all responsibilities of the company’s operations. Mr Shi Mingsheng, named as the Chief Operating Officer of CHBP, previously served as the chairman of Suzhou Erye Pharmaceutical Company Limited since 2003. In association with Ms Zhang Jian, he built a profitable business, which currently has a joint venture with China Biopharmaceuticals. Mr Ding Weihua, elected to the Board of Directors of the company, is a veteran in the pharmaceuticals industry having worked in the field for more than 33 years. Mr Ding worked for nine years as deputy general manager and manager in sales and marketing at Erye. Prior to his positions in Erye, he worked for six years in business planning at Jiangsu Nantong Qinfen Pharmaceutical Company. “These new appointments not only add depth to our management team but demonstrate our commitment to enhancing our corporate governance. The experience that all three members bring from our most successful subsidiary to date, Eyre, will have an immediate positive impact on the management and performance of China Biopharmaceuticals,” said Mr Chris Peng Mao, Chief Executive Officer of China Biopharmaceuticals....   more»

GlaxoSmithKline »23/05/2007 [Company watch]
Glaxo to unveil major China drug research centre

LONDON, May 23 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile , Research) is set to unveil plans for major research and development centre in China, joining a growing number of pharmaceutical companies tapping into the country's skillbase in life sciences. Research head Moncef Slaoui told the annual meeting of Europe's biggest drugmaker on Wednesday that an announcement on the investment in a fully integrated research and development facility was imminent....   more»

Amgen »22/05/2007 [Company watch]
Amgen (NASDAQ:AMGN) today announced that David Lacey, M.D., has been named senior vice president, head of Research, effective immediately.

Amgen (NASDAQ:AMGN) today announced that David Lacey, M.D., has been named senior vice president, head of Research, effective immediately. Over the past year, Lacey acted as the interim head of Research -- in addition to his role as Amgen South San Francisco site leader -- and demonstrated his ability to effectively manage Amgen's global Research organization, encompassing the company's Oncology/Hematology, Inflammation, Metabolic Disorders and Neuroscience therapeutic areas...   more»

GlaxoSmithKline »24/05/2007 [Company watch]
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai

Jingwu Zang to lead work on neurogenerative diseases GlaxoSmithKline (GSK) today announces the appointment of Jingwu Zang to head a new GSK research and development centre in Shanghai, China. His appointment, as Senior Vice President, will be effective in June....   more»

GlaxoSmithKline »29/05/2007 [Company watch]
GlaxoSmithKline set up a drug research centre in China.

GlaxoSmithKline (GSK) is the latest pharma heavyweight to set up a drug research centre in China....   more»

Bridgetech Holdings »29/05/2007 [Company watch]
Bridgetech Forms Strategic Alliance With ValiRx Plc to Foster Technology Transfer Between Europe and Greater China

Bridgetech Holdings International, Inc. a company focused on maximizing the potential of emerging healthcare products and services in the U.S. and Asian markets, today announced that it has signed a strategic alliance agreement with ValiRx plc, a biopharmaceutical company based in England. The agreement governs cooperative efforts in creating and exploiting market and technology transfer initiatives between Europe and Greater China....   more»

Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China to Receive $10 Million Investment from Lilly Asian Ventures

BioVeda China today announced a $10 Million investment from Lilly Asian Ventures. BioVeda China is the first international venture capital fund focusing on life-sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life-science industry in China....   more»

Sundia MediTech Company,Ltd. »06/06/2007 [Company watch]
China CROs Merge

Sundia MediTech and Shanghai United PharmaTech report that they will be merging. This is a first for China’s young CRO industry, acording to Sundia’s CEO, Wang Xiaochuan, Ph.D. Both Xiaochuan and United PharmaTech’s CEO, Shi Xiongwei, Ph.D., signed a letter of intent agreeing to combine their two companies. Under the terms of the merger, both United PharmaTech and Sundia MediTech will become subsidiaries of Sundia Investment Group, the British Virgin Islands-based holding company that currently owns Sundia MediTech. Dr. Wang will become the new company’s chairman and CEO, while Dr. Shi will hold the positions of director and executive vp. The former senior management teams of both companies will join together into a new, combined management team. Zhang Suyang, a partner of IDG VC, said that he believes China’s drug development CRO industry is beginning to emerge from its initial state into one in which companies will begin to consolidate. “The CRO companies, and the overall size of the CRO industry in China are still relatively small, and there is huge potential for growth, so we can expect that in the following few years there will be many mergers,” explained Zhang. “Companies in this industry will grow quickly and soon; we will see companies of reasonable size and with good governance emerge as corporations with serious long-term potential.” Part of the reason for the merger, noted Dr. Wang, is that it will combine United PharmaTech’s and Sundia’s technical expertise in different fields....   more»

Eli Lilly & Co »07/06/2007 [Company watch]
Lilly Announce $100 Million Investment in Research in China

Eli Lilly & Co, one of the world's leading pharmaceutical firms, plans to pour $100 million into China over the next five years to expand its drug research capacity in a bid to tap into the country's talent pool, its CEO said. The US drug maker will primarily beef up its research and development in biology, chemistry and clinical research areas, said John Lechleiter, president and CEO of Eli Lilly & Co....   more»

Charles River »10/06/2007 [Company watch]
Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd,

Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd, a Shanghai company that, like Charles River, provides pre-clinical CRO (Contract Research Organization) services. As one of the top two U.S. CROs, the menu of Charles River offerings are somewhat larger than BioExplorer's, although these will be expanded to meet the stated goal of supporting its customers’ needs, from drug discovery through proof of concept on a global basis....   more»

Sundia MediTech Company,Ltd. »08/06/2007 [Company watch]
Sundia Meditech Company, Ltd. celebrated its recent strong growth at the company's third anniversary party in Shanghai.

The main business of this company is to provide contracted research (CRO) services to pharmaceutical and biotech company clients worldwide. Earlier this week, the company announced a merger in process with United Pharmatech Company, another CRO company in Shanghai....   more»

Eli Lilly & Co »06/06/2007 [Company watch]
BioVeda China today announced a $10 Million investment from Lilly Asian Ventures.

BioVeda China is the first international venture capital fund focusing on life sciences investments in China. The investment has shown Lilly's commitment to expand its economic footprint in the fast growing life science industry in China....   more»

Hutchinson Meditech
»20/06/2007 [Company watch]
Meditech Pays $3.3 Million for R&D Facility

Building in Zhang Jiang High-Tech Park in Shanghai Hutchinson MediPharma Ltd., a division of Hutchinson China Meditech Ltd. (London: HCM) (see story), purchased for $3.3 million the R&D facility in Shanghai it currently occupies....   more»

Wuxi Pharma Tech
»06/07/2007 [Company watch]
IPO for WuXi PharmaTech?

Outsourcing powerhouse WuXi PharmaTech is rumored to be on the verge of announcing its IPO. The Shanghai-based company has been a huge success story right from the outset of its 2001 startup, now boasting 1,550 scientific staff members and over 2,000 employees overall....   more»

»03/07/2007 [Company watch]
GSK to Spend US$40 Million in R&D in China

GlaxoSmithKline (GSK) said yesterday that it will spend US$40 million this year to start a research facility in Shanghai that will grow into one of its largest research centers globally....   more»

China Sky One Medical,Inc. »05/07/2007 [Company watch]
China Sky One Medical Passes Recent SFDA Inspection

China Sky One Medical, Inc. , a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that its facilities and products passed a surprise inspection by China State Food and Drug Administration (SFDA) on June 28, 2007. Government officials and industry professionals working for the SFDA inspected the Company\\\\\\\'s production process, including the quality of raw materials, final packaging, consumer instructions, as well as stock-keeping methods...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.